Voyager Therapeutics, Inc. (NASDAQ:VYGR) Stake Decreased by Bridgeway Capital Management LLC

Bridgeway Capital Management LLC trimmed its holdings in Voyager Therapeutics, Inc. (NASDAQ:VYGR - Free Report) by 72.9% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 50,106 shares of the company's stock after selling 135,003 shares during the quarter. Bridgeway Capital Management LLC owned about 0.09% of Voyager Therapeutics worth $284,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Barclays PLC grew its stake in shares of Voyager Therapeutics by 55.8% in the third quarter. Barclays PLC now owns 104,462 shares of the company's stock worth $612,000 after purchasing an additional 37,398 shares in the last quarter. Allspring Global Investments Holdings LLC lifted its holdings in Voyager Therapeutics by 23.9% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 39,313 shares of the company's stock worth $223,000 after purchasing an additional 7,573 shares during the period. Raymond James Financial Inc. acquired a new stake in Voyager Therapeutics in the fourth quarter worth about $746,000. Rhumbline Advisers grew its position in Voyager Therapeutics by 3.4% in the 4th quarter. Rhumbline Advisers now owns 71,497 shares of the company's stock valued at $405,000 after buying an additional 2,354 shares in the last quarter. Finally, American Century Companies Inc. increased its stake in Voyager Therapeutics by 8.1% during the 4th quarter. American Century Companies Inc. now owns 122,726 shares of the company's stock valued at $696,000 after buying an additional 9,190 shares during the period. 48.03% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, CEO Alfred Sandrock sold 10,885 shares of the stock in a transaction on Wednesday, April 2nd. The stock was sold at an average price of $3.43, for a total transaction of $37,335.55. Following the completion of the sale, the chief executive officer now directly owns 430,931 shares in the company, valued at approximately $1,478,093.33. This trade represents a 2.46% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 6.39% of the company's stock.

Voyager Therapeutics Trading Up 5.7%

Shares of Voyager Therapeutics stock opened at $3.35 on Tuesday. Voyager Therapeutics, Inc. has a 1 year low of $2.75 and a 1 year high of $9.55. The company has a market cap of $185.38 million, a P/E ratio of 4.72 and a beta of 0.95. The stock has a 50-day moving average price of $3.50 and a 200 day moving average price of $4.89.

Voyager Therapeutics (NASDAQ:VYGR - Get Free Report) last posted its quarterly earnings results on Tuesday, May 6th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.35) by ($0.18). The company had revenue of $6.47 million during the quarter, compared to analysts' expectations of $13.55 million. Voyager Therapeutics had a return on equity of 8.33% and a net margin of 15.80%. On average, equities analysts forecast that Voyager Therapeutics, Inc. will post -0.91 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on VYGR shares. Wells Fargo & Company set a $10.00 price target on shares of Voyager Therapeutics and gave the company an "overweight" rating in a report on Wednesday, March 12th. Wedbush restated an "outperform" rating on shares of Voyager Therapeutics in a report on Wednesday, March 12th. Canaccord Genuity Group decreased their price target on shares of Voyager Therapeutics from $14.00 to $12.00 and set a "buy" rating on the stock in a research report on Thursday, March 13th. Cantor Fitzgerald reiterated an "overweight" rating on shares of Voyager Therapeutics in a research report on Wednesday, March 12th. Finally, HC Wainwright reissued a "buy" rating and set a $30.00 price objective on shares of Voyager Therapeutics in a research note on Tuesday, April 8th. One equities research analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Voyager Therapeutics has a consensus rating of "Buy" and a consensus target price of $13.97.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.